Abstract
We identified imported cases of a novel D614A mutation in the spike glycoprotein of SARS-CoV-2 in the South Korea. SARS-CoV-2 harboring the novel mutation was isolated from returning travelers from Uzbekistan. These results emphasized the possibility that new mutations have emerged in that area.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study did not require clinical trials.
Funding Statement
This work was supported by a grant from the Korea Centers for Disease Control and Prevention [4837-301-210]
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I confirm all relevant ethical guidelines have been followed, and this study was approved by the institutional review board (IRB) of Korea Centers for Disease Control and Prevention (IRB no. 2011- 05CON-04-C).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The source data for the Table along with the Supplementary Table presented in this paper are available upon request.
